3 min read
Selexis SA and Turgut Pharmaceuticals Advance Partnership with Third Commercial License Agreement
Supports Advancement of Biosimilar to Treat Two Ultra-Rare Diseases
Geneva, Switzerland, and Istanbul, Turkey, 20...
Geneva, Switzerland, and Istanbul, Turkey, 20...
Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical...
Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’...
Paper in Biotechnology and Bioengineering describes faster and more efficient technology for isolation of...
Geneva, Switzerland, 5 SEPTEMBER 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...
Geneva, Switzerland, 27 June 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...
Geneva, Switzerland and Menlo Park, CA, 12 JUNE 2017 – Selexis SA and TeneoBio, Inc. announced today that they have...
Geneva, Switzerland, 30 MAY 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian cell...
Geneva, Switzerland, and Nantes, France, 23 May 2017 – Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173;...
Geneva, Switzerland, 12 May 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...
Geneva, Switzerland, 14 MARCH 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...
Selexis SA Inks Agreement for Applications in Cancer and Infectious Disease Selexis to develop cell lines for three...
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.